Kurs & Likviditet
|Lista||First North Stockholm|
|2022-08-08||Extra Bolagsstämma 2022|
|2022-05-25||Ordinarie utdelning 2CUREX 0.00 SEK|
|2021-05-28||Ordinarie utdelning 2CUREX 0.00 SEK|
|2020-07-02||Extra Bolagsstämma 2020|
|2020-05-29||Ordinarie utdelning 2CUREX 0.00 SEK|
|2019-05-29||Ordinarie utdelning 2CUREX 0.00 SEK|
|2019-04-02||Extra Bolagsstämma 2019|
|2018-05-29||Ordinarie utdelning 2CUREX 0.00 SEK|
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that it has redefined its go-to-market strategy in North Europe. As a consequence, the distribution agreement with YourRad AB, covering Norway, Sweden, and Finland, has been terminated. The new distributor in Finland will be Algol Diagnostics Oy, a company belonging to the Algol Group. Commercial operations in Norway and Sweden will be taken over directly by 2cureX, who also announced starting direct activities in Germany to get the IndiTreat® tests included in hospital guidelines there.
2cureX has announced today a new go-to-market strategy to strengthen its commercial activities in the North of Europe. The distribution contract that 2cureX had with the company YourRad AB since March 2020, covering Sweden, Norway and Finland, has been terminated by mutual agreement between the parties.
Instead, 2cureX has signed a distribution agreement with Algol Diagnostics Oy, a company belonging to the Algol Group, to commercialize IndiTreat® in Finland. Under the terms of the collaboration, Algol Diagnostics will promote IndiTreat® to oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen.
Commercial operations in Sweden, Norway and Germany will be conducted directly by 2cureX, who is already in charge of the commercialization in Denmark. The company expects that the direct interaction with customers in Sweden and Norway will result in a faster rollout of the IndiTreat® tests. The activities in Germany will initially aim at engaging local Key Opinion Leaders through the IGNITE program to support the inclusion of the test in the hospital guidelines.
Getting closer to the customers in 2cureX home markets
“We are thrilled to welcome Algol Diagnostics as our partner in Finland. They are a very strong player in the diagnostic field and have a synergistic product portfolio, and we are confident that they will succeed in commercializing IndiTreat® in their country”, said Fernando Andreu, CEO of 2cureX. “Conducting direct operations in Norway, Sweden, and Germany, we will be closer to our customers in what we consider to be our home markets and expect a faster rollout of IndiTreat® as a consequence. I want to take the opportunity to thank YourRad for the collaboration in the last two years”.
Building a critical mass of early users
Johan Wulff, Managing Director of Algol Diagnostics: “We have systematically developed our pathology diagnostics portfolio towards automatization and digitalization, contributing to fast and accurate patient diagnosis. Adding innovative tests like IndiTreat® makes our product offering even better. Leveraging our strong relationships to hospitals in Finland, we want to take an active role in helping healthcare professionals in Finland provide more personalized care to cancer patients”.
Nordic Region, at the forefront of precision oncology
“In the last years the Nordic countries have developed a strong ecosystem for precision oncology, including several initiatives to incorporate innovative diagnostic approaches. With a direct presence in Scandinavia and the collaboration with Algol in Finland we think we are in a better position to be a relevant player in that ecosystem” said Jesper Floyd Kristiansen, VP Business Development at 2cureX.
The Algol agreement has been signed for an initial term of three years. Other terms of the agreement have not been disclosed. Sales impact of this agreement is expected to show in 2022.